Research and Development

Showing 15 posts of 9603 posts found.

Sanofi-Aventis headquarters

Sanofi signs ophthalmology research collaboration

March 25, 2011 Research and Development Fovea, Sanofi-Aventis, Vision Institute, ophthalmology

Sanofi-Aventis has penned a collaboration with one of the main eye disease research centres in Europe. The three-year agreement between …

Cephalon buys Gemin X for $225 million

March 24, 2011 Research and Development Cephalon, lung cancer

Cephalon is to acquire oncology specialist Gemin X and gain access to its cancer candidate obatoclax. The US biopharmaceutical firm …
aquapharm_bertrand_lehuu

Bertrand Lehuu joins Aquapharm

March 24, 2011 Research and Development appointment, research and development

Scottish marine biotechnology company Aquapharm Biodiscovery has appointed Bertrand Lehuu as senior VP – pharma business. Bertrand has almost 30 …

Budget provides UK science incentives

March 24, 2011 Research and Development George Osborne, R&D tax credits, clinical trials

Chancellor George Osborne has unveiled tax incentives, new funding and moves to cut red tape for the life sciences sector …
GlaxoSmithKline office

GSK to fund schools science programme

March 23, 2011 Research and Development, Sales and Marketing GSK, GlaxoSmithKline, King's College, school science

GlaxoSmithKline has followed its pledge to refund the tuition fees of UK graduates it takes on with a less direct …

BMS skin cancer vaccine hits phase III target

March 23, 2011 Research and Development BMS, Bristol-Myers Squibb, advanced inoperable skin cancer, advanced melanoma, cancer drugs, cancer vaccine, ipilimumab

Bristol Myers Squibb’s cancer vaccine ipilimumab has increased overall survival in advanced melanoma patients. The therapy was being tested as …
Roche's Swiss headquarters

Roche’s skin cancer drug passes mid-stage trial

March 22, 2011 Research and Development Curis, Roche, advanced basal cell carcinoma, skin cancer, vismodegib

Roche’s skin cancer candidate vismodegib has met its primary endpoint in a phase II trial. The drug is being tested …

GSK Parkinson’s drug impresses at phase III

March 21, 2011 Research and Development ADVANCE-PD, GSK, GlaxoSmithKline, IPX066, Impax Pharmaceuticals, Parkinson's disease, Parkinson’s disease

GlaxoSmithKline’s advanced Parkinson’s disease drug IPX066 has impressed in a head to head trial against it nearest rival. The phase …
Obesity

Takeda obesity drug falters at phase II

March 18, 2011 Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide

Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
efpia_lif_richard_bergstrom

Richard Bergström takes DG role at EFPIA

March 18, 2011 Research and Development, Sales and Marketing Brian Ager, EFPIA, Richard Bergstrom, appointment, research and development, sales and marketing

European pharma industry association EFPIA has appointed Richard Bergström as its new director general. He takes over from Brian Ager, …

Biotech lobbies for further UK tax breaks

March 17, 2011 Research and Development BIA, R&D tax credits, biotech

Biotech companies are calling on Chancellor George Osborne to provide extra incentives for research in his forthcoming Budget. The budget …
merck_sharp_dohme_deepak_khanna

MSD’s Deepak Khanna to chair American Pharmaceutical Group

March 17, 2011 Research and Development, Sales and Marketing American Pharmaceutical Group, Deepak Khanna, MSD, merck sharp and dohme

Merck Sharp and Dohme’s UK managing director Deepak Khanna has been appointed chairman of the American Pharmaceutical Group. The APG …
novartis

Novartis to close UK manufacturing site, research downsized

March 16, 2011 Research and Development Horsham, Novartis, respiratory

Novartis is to close its manufacturing site in Horsham, West Sussex, but will retain its work in respiratory research at …
Novarits

Novartis to close UK research site

March 16, 2011 Research and Development Horsham, Novartis, job cuts, pharma job cuts

[UPDATE: Novartis has confirmed it will close its manufacturing site in Horsham, but continue to conduct respiratory research at the site …

New Regulatory & Pharmacovigilance training webinars available

March 15, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Wainwright Associates have designed a multitude of courses on general and specific regulatory & pharmacovigilance topics including:• Analytical Validation• Appeals, Hearings and …
The Gateway to Local Adoption Series

Latest content